BlackRock’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $235K | Sell |
31,361
-7,789
| -20% | -$82.3K | ﹤0.01% | 4773 |
|
|
2026
Q1 | $443K | Buy |
39,150
+622
| +2% | +$8.49K | ﹤0.01% | 4560 |
|
|
2025
Q4 | $493K | Buy |
38,528
+288
| +0.8% | +$4.43K | ﹤0.01% | 4488 |
|
|
2025
Q3 | $714K | Buy |
38,240
+959
| +3% | +$18.9K | ﹤0.01% | 4381 |
|
|
2025
Q2 | $954K | Buy |
37,281
+5,916
| +19% | +$119K | ﹤0.01% | 4266 |
|
|
2025
Q1 | $627K | Hold |
31,365
| – | – | ﹤0.01% | 4330 |
|
|
2024
Q4 | $571K | Hold |
31,365
| – | – | ﹤0.01% | 4375 |
|
|
2024
Q3 | $941K | Sell |
31,365
-1,425
| -4% | -$31.3K | ﹤0.01% | 4189 |
|
|
2024
Q2 | $461K | Sell |
32,790
-3,332
| -9% | -$57.8K | ﹤0.01% | 4366 |
|
|
2024
Q1 | $686K | Sell |
36,122
-194
| -0.5% | -$3.78K | ﹤0.01% | 4297 |
|
|
2023
Q4 | $806K | Sell |
36,316
-22
| -0.1% | -$653 | ﹤0.01% | 4312 |
|
|
2023
Q3 | $1.37M | Sell |
36,338
-1,663
| -4% | -$95.5K | ﹤0.01% | 4136 |
|
|
2023
Q2 | $2.73M | Buy |
38,001
+756
| +2% | +$47.8K | ﹤0.01% | 3927 |
|
|
2023
Q1 | $2.51M | Buy |
37,245
+142
| +0.4% | +$8.52K | ﹤0.01% | 3945 |
|
|
2022
Q4 | $1.15M | Buy |
37,103
+34
| +0.1% | +$1.01K | ﹤0.01% | 4367 |
|
|
2022
Q3 | $1.01M | Sell |
37,069
-179
| -0.5% | -$6.99K | ﹤0.01% | 4477 |
|
|
2022
Q2 | $1.63M | Sell |
37,248
-92,774
| -71% | -$4.26M | ﹤0.01% | 4336 |
|
|
2022
Q1 | $8.3M | Sell |
130,022
-1,539
| -1% | -$110K | ﹤0.01% | 3678 |
|
|
2021
Q4 | $11M | Buy |
131,561
+3,621
| +3% | +$406K | ﹤0.01% | 3616 |
|
|
2021
Q3 | $20.8M | Sell |
127,940
-4,118
| -3% | -$669K | ﹤0.01% | 3247 |
|
|
2021
Q2 | $19.9M | Sell |
132,058
-9,372
| -7% | -$1.58M | ﹤0.01% | 3309 |
|
|
2021
Q1 | $24.6M | Buy |
141,430
+3,316
| +2% | +$632K | ﹤0.01% | 3073 |
|
|
2020
Q4 | $22M | Buy |
138,114
+3,437
| +3% | +$575K | ﹤0.01% | 2950 |
|
|
2020
Q3 | $21.5M | Buy |
134,677
+20,388
| +18% | +$3.68M | ﹤0.01% | 2819 |
|
|
2020
Q2 | $22.6M | Buy |
114,289
+9,457
| +9% | +$1.74M | ﹤0.01% | 2732 |
|
|
2020
Q1 | $16.2M | Buy |
104,832
+1,852
| +2% | +$187K | ﹤0.01% | 2717 |
|
|
2019
Q4 | $7.93M | Sell |
102,980
-29
| -0% | -$2.53K | ﹤0.01% | 3352 |
|
|
2019
Q3 | $10.4M | Buy |
103,009
+2,603
| +3% | +$303K | ﹤0.01% | 3191 |
|
|
2019
Q2 | $13.3M | Buy |
100,406
+1,089
| +1% | +$150K | ﹤0.01% | 3075 |
|
|
2019
Q1 | $15M | Buy |
99,317
+35
| +0% | +$5.45K | ﹤0.01% | 2900 |
|
|
2018
Q4 | $16M | Buy |
99,282
+1,195
| +1% | +$237K | ﹤0.01% | 2840 |
|
|
2018
Q3 | $25.3M | Buy |
98,087
+12,745
| +15% | +$3.2M | ﹤0.01% | 2738 |
|
|
2018
Q2 | $19.5M | Buy |
85,342
+78,552
| +1,157% | +$14.9M | ﹤0.01% | 2880 |
|
|
2018
Q1 | $958K | Sell |
6,790
-217
| -3% | -$32.8K | ﹤0.01% | 3891 |
|
|
2017
Q4 | $911K | Buy |
7,007
+166
| +2% | +$21.1K | ﹤0.01% | 3920 |
|
|
2017
Q3 | $848K | Buy |
6,841
+1,232
| +22% | +$126K | ﹤0.01% | 3957 |
|
|
2017
Q2 | $483K | Sell |
5,609
-350
| -6% | -$30.7K | ﹤0.01% | 4031 |
|
|
2017
Q1 | $536K | Buy |
5,959
+5,939
| +29,695% | +$664K | ﹤0.01% | 3945 |
|
|
2016
Q4 | $2K | Hold |
20
| – | – | ﹤0.01% | 3628 |
|
|
2016
Q3 | $3K | Buy |
+20
| New | +$2.08K | ﹤0.01% | 3546 |
|
Other funds holding CTSO
CM
BlackRock's CTSO Position: Q2 2026 in Review
BlackRock reduced its Cytosorbents Corp (CTSO) stake by 20% in Q2 2026, selling an estimated $82.3K and leaving 31,361 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #4773.
BlackRock first reported a position in CTSO in Q3 2016 and has held it in 40 quarters since. The position peaked at $25.3M in Q3 2018. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- BlackRock held 31,361 shares of Cytosorbents Corp worth $235K as of Q2 2026.
- BlackRock sold 7,789 Cytosorbents Corp shares in Q2 2026, an estimated $82.3K.
- Cytosorbents Corp made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4773 holding.
- BlackRock first reported a position in Cytosorbents Corp in Q3 2016 and has held it in 40 quarters since.
- BlackRock's Cytosorbents Corp position peaked at $25.3M in Q3 2018.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.